Drug intelligence / Profile preview

AMB305

Development stage: Preclinical
Lead developer: Aimed Bio
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Parenteral

Overview

AMB305 is an antibody-drug conjugate (ADC) currently in preclinical development for the treatment of solid tumors. It is being co-developed by **Aimed Bio**, a spin-off from Samsung Medical Center, and **GeneQuantum Healthcare**. The asset utilizes GeneQuantum's proprietary site-specific enzymatic conjugation technology, known as the **iGDC (intelligent Gene-encoded Device-conjugated)** platform. This platform is designed to produce highly homogeneous ADCs with a stable drug-to-antibody ratio (DAR), which aims to enhance the therapeutic window and stability compared to traditional random conjugation methods. As of 2024, AMB305 is in the candidate selection phase, and its specific molecular target remains undisclosed by the developers.

Beyond the preview

Go deeper on AMB305.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMB305.

Explore the full profile